GlobeStar Therapeutics Co. (OTCMKTS:GSTC) Short Interest Up 934.4% in March

GlobeStar Therapeutics Co. (OTCMKTS:GSTC) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 33,100 shares, an increase of 934.4% from the February 28th total of 3,200 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 1,865,900 shares, the short-interest ratio is presently 0.0 days.

GlobeStar Therapeutics Price Performance

GlobeStar Therapeutics stock traded down $0.00 during mid-day trading on Thursday, reaching $0.00. 2,615,000 shares of the company traded hands, compared to its average volume of 3,260,735. GlobeStar Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.00.

GlobeStar Therapeutics Company Profile

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc and changed its name to GlobeStar Therapeutics Corporation in July 2021.